Reseach Progress and Future of Phage Therapy in Klebsiella Pneumoniae Infection
DOI:
https://doi.org/10.54097/m72eeq11Keywords:
Bacteriophage, phage therapy, Klebsiella pneumoniae, antibiotic resistance.Abstract
Bacteriophages are widely found in nature and can specifically lyse bacterial viruses. Because of the extensive use and abuse of antibiotics, bacterial resistance has become a global problem. Klebsiella pneumoniae is one of the most common clinical drug-resistant bacteria, and the incidence is increasing year by year. Because many strains of Klebsiella pneumoniae are multidrug-resistant, treatment has been difficult. And this resistance has been increasing in recent years, adding to this many new difficulties due to the misuse of antibiotics. The phage can be a new way treat Klebsiella pneumoniae by lysis, which is non-toxic, non-secondary drug resistance, highly specific and penetrating, however, it has not been widely used in clinical practice and only a few cases have been reported. Through the in-depth study of phages, can play an important role in drug-resistant Klebsiella pneumoniae. The paper will introduce the characteristic Klebsiella pneumoniae and phage therapy, and also summarize development of Current animal models and clinical trials of phage therapy in Klebsiella pneumoniae.
Downloads
References
Podschun, R.. (1998) Klebsiella spp. as nosocomial pathogens: Epidemiology, taxonomy, typing methods, and pathogenicity factors, Clinical Microbiology Reviews.
Sofy, A.R.. (2021a) Characterization and full genome sequence of novel KPP-5 lytic phage against Klebsiella pneumoniae responsible for recalcitrant infection, MDPI.
Chhibber, S., Kaur, S. and Kumari, S. (2008) Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae b5055-mediated lobar pneumonia in mice, microbiologyresearch.org.
Lee, C.-R. et al. (2017) Antimicrobial resistance of hypervirulent Klebsiella pneumoniae: Epidemiology, hypervirulence-associated determinants, and resistance mechanisms, Frontiers.
Moradigaravand D, Martin V, Peacock SJ,et al. Population structure of multidrug-resistant Klebsiella oxytoca within hospitals across the United Kingdom and ireland identifies sharing of virulence and resistance genes with K. pneumoniae. Genome Biol Evol 2017;9:574–584
Reardon, S. Phage therapy gets revitalized. Nature 2014, 510, 15–16. [CrossRef] [PubMed]
Chhibber, S.; Kaur, S.; Kumari, S. Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J. Med. Microbiol. 2008, 57, 1508–1513
Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. 2019. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med 25:730–733.
Chhibber, S.; Kaur, S.; Kumari, S. Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J. Med. Microbiol. 2008, 57, 1508–1513.
Li lisha, Li Jianhui, He bin, et al. Bacteriophage in the treatment of drug-resistant Klebsiella pneumoniae pulmonary infection: clinical application and efficacy, Shanghai Jiao Tong University [ J ]2021,41(9)1272-1276.
Kumari S, Harjai K, Chhibber S. 2010. Evidence to support the therapeutic potential of bacteriophage Kpn5 in burn wound infection caused by Klebsiella pneumoniae in BALB/c mice. J Microbiol Biotechnol 20:935–941
Gill JJ, Hyman P. 2010. Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol 11:2–14.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







